Literature DB >> 34244600

Novel PRMT7 mutation in a rare case of dysmorphism and intellectual disability.

Jessie Poquérusse1,2, Whitney Whitford1,2, Juliet Taylor3, Salam Alburaiky3, Russell G Snell1,2, Klaus Lehnert1,2, Jessie C Jacobsen4,5.   

Abstract

Protein arginine N-methyltransferase 7 (PRMT7) encodes an arginine methyltransferase central to a number of fundamental biological processes, mutations in which result in an autosomal recessive developmental disorder characterized by short stature, brachydactyly, intellectual developmental disability and seizures (SBIDDS). To date, fewer than 15 patients with biallelic mutations in PRMT7 have been documented. Here we report brothers from a consanguineous Iraqi family presenting with a developmental disorder characterized by global developmental delay, shortened stature, facial dysmorphisms, brachydactyly, and kidney dysfunction. In both affected brothers, whole genome sequencing (WGS) identified a novel homozygous substitution in PRMT7 (ENST00000339507.5), c.1097 G > A (p.Cys366Tyr), considered to account for the majority of the phenotypic presentation. Rare compound heterozygous mutations in the dysplasia-associated perlecan-encoding HSPG2 gene (ENST00000374695.3) were also found (c.10721-2dupA, p.Ser71Asn and c.212 G > A), potentially accounting for the kidney dysfunction. In addition to expanding the known mutational spectrum of variably expressive PRMT7 mutations alongside potential digenic inheritance with HSPG2, this report underlines the diagnostic utility of a WGS-guided analysis in the detection of rare genetic disorders.
© 2021. The Author(s), under exclusive licence to The Japan Society of Human Genetics.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 34244600     DOI: 10.1038/s10038-021-00955-5

Source DB:  PubMed          Journal:  J Hum Genet        ISSN: 1434-5161            Impact factor:   3.172


  40 in total

1.  Prenatal and postnatal presentation of PRMT7 related syndrome: Expanding the phenotypic manifestations.

Authors:  Roee Birnbaum; Naama Yosha-Orpaz; Miri Yanoov-Sharav; Dvora Kidron; Hila Gur; Keren Yosovich; Tally Lerman-Sagie; Gustavo Malinger; Dorit Lev
Journal:  Am J Med Genet A       Date:  2018-12-04       Impact factor: 2.802

Review 2.  Histone arginine methylation.

Authors:  Alessandra Di Lorenzo; Mark T Bedford
Journal:  FEBS Lett       Date:  2010-11-11       Impact factor: 4.124

3.  The Genotype-Tissue Expression (GTEx) Project.

Authors:  Latarsha J Carithers; Helen M Moore
Journal:  Biopreserv Biobank       Date:  2015-10       Impact factor: 2.300

4.  PRMT7 Preserves Satellite Cell Regenerative Capacity.

Authors:  Roméo Sébastien Blanc; Gillian Vogel; Taiping Chen; Colin Crist; Stéphane Richard
Journal:  Cell Rep       Date:  2016-02-04       Impact factor: 9.423

5.  Symmetric dimethylation of H3R2 is a newly identified histone mark that supports euchromatin maintenance.

Authors:  Valentina Migliori; Julius Müller; Sameer Phalke; Diana Low; Marco Bezzi; Wei Chuen Mok; Sanjeeb Kumar Sahu; Jayantha Gunaratne; Paola Capasso; Christian Bassi; Valentina Cecatiello; Ario De Marco; Walter Blackstock; Vladimir Kuznetsov; Bruno Amati; Marina Mapelli; Ernesto Guccione
Journal:  Nat Struct Mol Biol       Date:  2012-01-08       Impact factor: 15.369

6.  Prmt7 Deficiency Causes Reduced Skeletal Muscle Oxidative Metabolism and Age-Related Obesity.

Authors:  Hyeon-Ju Jeong; Hye-Jin Lee; Tuan Anh Vuong; Kyu-Sil Choi; Dahee Choi; Sung-Hoi Koo; Sung Chun Cho; Hana Cho; Jong-Sun Kang
Journal:  Diabetes       Date:  2016-04-26       Impact factor: 9.461

7.  Loss of the arginine methyltranserase PRMT7 causes syndromic intellectual disability with microcephaly and brachydactyly.

Authors:  K D Kernohan; A McBride; Y Xi; N Martin; J Schwartzentruber; D A Dyment; J Majewski; S Blaser; K M Boycott; D Chitayat
Journal:  Clin Genet       Date:  2016-11-30       Impact factor: 4.438

8.  Discovery of four recessive developmental disorders using probabilistic genotype and phenotype matching among 4,125 families.

Authors:  Nadia Akawi; Jeremy McRae; Morad Ansari; Meena Balasubramanian; Moira Blyth; Angela F Brady; Stephen Clayton; Trevor Cole; Charu Deshpande; Tomas W Fitzgerald; Nicola Foulds; Richard Francis; George Gabriel; Sebastian S Gerety; Judith Goodship; Emma Hobson; Wendy D Jones; Shelagh Joss; Daniel King; Nikolai Klena; Ajith Kumar; Melissa Lees; Chris Lelliott; Jenny Lord; Dominic McMullan; Mary O'Regan; Deborah Osio; Virginia Piombo; Elena Prigmore; Diana Rajan; Elisabeth Rosser; Alejandro Sifrim; Audrey Smith; Ganesh J Swaminathan; Peter Turnpenny; James Whitworth; Caroline F Wright; Helen V Firth; Jeffrey C Barrett; Cecilia W Lo; David R FitzPatrick; Matthew E Hurles
Journal:  Nat Genet       Date:  2015-10-05       Impact factor: 38.330

9.  Pharmacological inhibition of PRMT7 links arginine monomethylation to the cellular stress response.

Authors:  Yoshinori Ishikawa; Shawna Organ; Nozomu Sakai; Fengling Li; Magdalena M Szewczyk; Levon Halabelian; Suzanne Ackloo; Amber L Couzens; Mohammad Eram; David Dilworth; Hideto Fukushi; Rachel Harding; Carlo C Dela Seña; Tsukasa Sugo; Kozo Hayashi; David McLeod; Carlos Zepeda; Ahmed Aman; Maria Sánchez-Osuna; Eric Bonneil; Shinji Takagi; Rima Al-Awar; Mike Tyers; Stephane Richard; Masayuki Takizawa; Anne-Claude Gingras; Cheryl H Arrowsmith; Masoud Vedadi; Peter J Brown; Hiroshi Nara; Dalia Barsyte-Lovejoy
Journal:  Nat Commun       Date:  2020-05-14       Impact factor: 14.919

10.  Profiling PRMT methylome reveals roles of hnRNPA1 arginine methylation in RNA splicing and cell growth.

Authors:  Wen-Juan Li; Yao-Hui He; Jing-Jing Yang; Guo-Sheng Hu; Yi-An Lin; Ting Ran; Bing-Ling Peng; Bing-Lan Xie; Ming-Feng Huang; Xiang Gao; Hai-Hua Huang; Helen He Zhu; Feng Ye; Wen Liu
Journal:  Nat Commun       Date:  2021-03-29       Impact factor: 14.919

View more
  1 in total

Review 1.  Cellular pathways influenced by protein arginine methylation: Implications for cancer.

Authors:  Jian Xu; Stéphane Richard
Journal:  Mol Cell       Date:  2021-10-06       Impact factor: 17.970

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.